Checkpoint Trend

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE396H01019
  • NSEID:
  • BSEID: 531099
INR
129.10
2.5 (1.97%)
BSENSE

Jan 19

BSE+NSE Vol: 8.56 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

8.56 k (162.11%) Volume

Shareholding (Dec 2025)

FII

10.71%

Held by 3 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

0.00%

how big is Checkpoint Trend?

06-Jun-2025

As of Jun 06, Checkpoint Trends Ltd has a market capitalization of 10.00 Cr, with recent net sales of 0.50 Cr and a net profit of 0.02 Cr over the last four quarters. Shareholder's funds are 0.53 Cr, and total assets are 0.93 Cr as of Mar'24.

Market Cap: As of Jun 06, Checkpoint Trends Ltd has a market capitalization of 10.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Mar'25, Dec'24, Sep'24, and Jun'24, is 0.50 Cr. The sum of Net Profit for the same quarters is 0.02 Cr. This data is presented on a Standalone basis.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 0.53 Cr, while Total Assets amount to 0.93 Cr.

View full answer

When is the next results date for Checkpoint Trend?

06-Jun-2025

No Upcoming Board Meetings

Who are in the management team of Checkpoint Trend?

06-Jun-2025

As of March 2022, the management team of Checkpoint Trend includes Abha Kapoor (CFO), Sunil Khandelwal (Managing Director), Ritu Chhatani (Company Secretary), and independent directors Sneha Thakur, Gopal Sahu, and Harish Surve, who oversee operations and compliance.

As of March 2022, the management team of Checkpoint Trend includes the following members:<BR><BR>1. Abha Kapoor - Director (Finance) & CFO<BR>2. Sneha Thakur - Independent Director<BR>3. Sunil Khandelwal - Managing Director<BR>4. Gopal Sahu - Independent Director<BR>5. Ritu Chhatani - Company Secretary & Compliance Officer<BR>6. Harish Surve - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and ensuring compliance with regulations.

View full answer

What does Checkpoint Trend do?

06-Jun-2025

Checkpoint Trends Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology sector, providing trading and consulting services. As of March 2025, it reported net sales and net profit of 0 Cr, with a market cap of Rs 9 Cr.

Overview: <BR>Checkpoint Trends Ltd is engaged in the business of trading and provides various consulting services within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History: <BR>Checkpoint Trends Ltd was established in 1991 and was formerly known as Rubra Medicaments Ltd. The company name was changed in April 2022. The latest quarterly results reported net sales and net profit of 0 Cr for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 9 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 10.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.04 <BR>Return on Equity: 1.71% <BR>Price to Book: 9.70 <BR><BR>Contact Details: <BR>Address: 604 6th Floor Meghdoot, Mogul Lines Staff CHSL JVPD Sc Mumbai Maharashtra : 400049 <BR>Tel: 91-9167469649 <BR>Email: rubraltd@gmail.com <BR>Website: http://www.rubramed.com

View full answer

Has Checkpoint Trend declared dividend?

06-Jun-2025

No Dividend History Available

Who are the peers of the Checkpoint Trend?

03-Jun-2025

Peers of Checkpoint Trend include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Checkpoint Trend has a 1-year return of 110.41%, outperforming its peers, while management risk varies from excellent to below average across the group.

Peers: The peers of Checkpoint Trend are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Unjha Formul., Vivanza Biosci., Cian Healthcare, Beryl Drugs, and Ortin Global.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Average management risk is noted at Unjha Formul., Cian Healthcare, Beryl Drugs, and Ortin Global, while Below Average management risk is seen at Vivanza Biosci. and Checkpoint Trend. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, Below Average for Divi's Lab., Torrent Pharma, Unjha Formul., Cian Healthcare, Beryl Drugs, Ortin Global, and Checkpoint Trend, and Below Average for Vivanza Biosci. Capital Structure is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, Good for Torrent Pharma and Unjha Formul., and Below Average for Divi's Lab., Vivanza Biosci., Checkpoint Trend, Cian Healthcare, Beryl Drugs, and Ortin Global.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the peer with the lowest is Vivanza Biosci. at -60.94%. Checkpoint Trend's own 1-year return is 110.41%, which is significantly higher than all peers. Additionally, Unjha Formul., Vivanza Biosci., Cian Healthcare, Beryl Drugs, and Ortin Global all have negative six-month returns.

View full answer

What is the technical trend for Checkpoint Trend?

09-Jun-2025

As of May 29, 2025, Checkpoint Trend shows a mildly bullish outlook, supported by daily moving averages and monthly KST, despite some short-term bearish signals from weekly MACD and RSI.

As of 29 May 2025, the technical trend for Checkpoint Trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating mild bullishness and the monthly KST remaining bullish. However, the weekly MACD and RSI are showing mildly bearish and bearish signals respectively, which temper the overall bullish outlook. The Bollinger Bands are also indicating mild bullishness on both weekly and monthly time frames. Overall, while there are some bearish signals in the short term, the longer-term indicators suggest a cautiously optimistic view.

View full answer

Who are the top shareholders of the Checkpoint Trend?

17-Jul-2025

The top shareholders of Checkpoint Trend are individual investors with 71.77% of shares, followed by Religare Finvest Ltd at 5.89%, and two foreign institutional investors holding a combined 10.85%. There are no pledged promoter holdings or mutual funds in the shareholding structure.

The top shareholders of Checkpoint Trend include individual investors, who hold a significant 71.77% of the shares. Additionally, Religare Finvest Ltd is the highest public shareholder with a stake of 5.89%. The company also has two foreign institutional investors (FIIs) holding a combined 10.85%. There are no pledged promoter holdings or mutual funds involved in the shareholding structure.

View full answer

How has been the historical performance of Checkpoint Trend?

13-Nov-2025

Checkpoint Trend's historical performance shows a decline in net sales from 2.01 Cr in Mar'22 to 0.50 Cr in Mar'25, with total operating income and expenditures also decreasing. However, operating profit improved from a loss in Mar'23 to a profit in Mar'25, while total assets and liabilities decreased, indicating a stagnant cash position.

Answer:<BR>The historical performance of Checkpoint Trend shows a fluctuating trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Checkpoint Trend's net sales have seen a decline from 2.01 Cr in Mar'22 to 0.50 Cr in Mar'25, with a notable drop from 1.16 Cr in Mar'23. The total operating income followed a similar trend, decreasing from 2.01 Cr in Mar'22 to 0.50 Cr in Mar'25. The company's total expenditure, excluding depreciation, also decreased from 2.03 Cr in Mar'22 to 0.44 Cr in Mar'25. Operating profit (PBDIT) showed a slight improvement, moving from a loss of 0.08 Cr in Mar'23 to a profit of 0.06 Cr in Mar'25. Profit before tax improved from a loss of 0.08 Cr in Mar'23 to a profit of 0.05 Cr in Mar'25, while profit after tax remained stable at 0.03 Cr for both Mar'24 and Mar'25. The company's total assets decreased from 0.93 Cr in Mar'24 to 0.65 Cr in Mar'25, and total liabilities also declined from 0.93 Cr to 0.65 Cr in the same period. Cash flow figures indicate no cash inflow or outflow across the years, reflecting a stagnant cash position.

View full answer

Are Checkpoint Trend latest results good or bad?

13-Nov-2025

Checkpoint Trends' latest results show impressive revenue growth, with net sales up 827.33% quarter-on-quarter and a return to profitability with a net profit of ₹1.32 crore. However, significant concerns arise from a drastic drop in operating margins to 1.65% and an extremely high price-to-earnings ratio of 492x, indicating potential risks for investors.

The latest results for Checkpoint Trends present a mixed picture. On one hand, the company achieved remarkable revenue growth, with net sales increasing by 827.33% quarter-on-quarter and an astonishing 217,080% year-on-year. This growth has translated into a net profit of ₹1.32 crore, marking a significant turnaround from previous losses.<BR><BR>However, the results also reveal significant concerns regarding profitability. Operating margins have plummeted from 36.00% in the previous quarter to just 1.65% in the latest quarter. This drastic compression raises questions about the sustainability of the company's growth, as it suggests that the company may be prioritizing volume over profitability.<BR><BR>Additionally, despite the impressive revenue figures, the company's overall financial health is precarious, with a low return on equity and a high valuation relative to its earnings. The stock trades at a price-to-earnings ratio of 492x, which is extraordinarily high compared to industry averages.<BR><BR>In summary, while Checkpoint Trends has demonstrated explosive growth in sales and a return to profitability, the sharp decline in margins and extreme valuation multiples indicate potential risks that investors should carefully consider.

View full answer

Should I buy, sell or hold Checkpoint Trend?

14-Nov-2025

Is Checkpoint Trend overvalued or undervalued?

14-Nov-2025

As of November 13, 2025, Checkpoint Trend is considered undervalued with a favorable valuation grade shift, featuring a PE ratio of 30.19 and a year-to-date return of 512.18%, significantly outperforming its peers and the Sensex.

As of 13 November 2025, Checkpoint Trend's valuation grade has moved from very expensive to attractive, indicating a significant shift in its market perception. The company is currently assessed as undervalued, particularly in light of its impressive financial metrics. Key ratios include a PE ratio of 30.19, an EV to EBITDA ratio of 22.62, and a PEG ratio of 0.04, which suggests strong growth potential relative to its price.<BR><BR>In comparison to its peers, Checkpoint Trend's valuation appears favorable. For instance, Sun Pharma has a PE ratio of 36.15 and an EV to EBITDA of 23.85, while Cipla, which is also rated attractive, has a PE of 22.65. Notably, Checkpoint Trend's return performance has significantly outpaced the Sensex, with a year-to-date return of 512.18% compared to the Sensex's 8.11%, reinforcing the notion that the stock is undervalued relative to its growth trajectory.

View full answer

Why is Checkpoint Trends Ltd falling/rising?

18-Jan-2026

As of 18-Jan, Checkpoint Trends Ltd's stock price is rising to 126.60, driven by strong financial performance, increased investor interest, and a significant outperformance relative to its sector. The stock has shown a total return of 3.98% over the last two days and a remarkable annual return of 1054.06%.

As of 18-Jan, Checkpoint Trends Ltd's stock price is rising, currently at 126.60, reflecting an increase of 2.45 (1.97%). This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 3.08% today and has shown a consecutive gain over the last two days, with a total return of 3.98% in that period. Additionally, there has been a significant increase in investor participation, with delivery volume rising by 169.8% compared to the 5-day average, indicating heightened interest in the stock.<BR><BR>Moreover, the company's strong financial performance supports its rising stock price. Checkpoint Trends Ltd has demonstrated high management efficiency, evidenced by a return on equity (ROE) of 17.29% and a low debt-to-equity ratio of 0.05 times. The company has also reported healthy long-term growth, with net sales increasing at an annual rate of 160.84%. Positive results over the last three consecutive quarters further bolster investor confidence, with key financial metrics reaching their highest levels.<BR><BR>The stock's impressive performance over the past year, generating a return of 1054.06%, significantly outpaces the market's average returns, contributing to its rising price. Overall, the combination of strong financial indicators, increased investor interest, and consistent performance relative to the market are key reasons for the rise in Checkpoint Trends Ltd's stock price.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

High Management Efficiency with a high ROE of 17.29%

 
2

Company has a low Debt to Equity ratio (avg) at 0.05 times

 
3

Healthy long term growth as Net Sales has grown by an annual rate of 160.84%

 
4

The company has declared Positive results for the last 3 consecutive quarters

5

With ROE of 73.5, it has a Fair valuation with a 35.1 Price to Book Value

6

Majority shareholders : Non Institution

 
7

Consistent Returns over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 69 Cr (Micro Cap)

stock-summary
P/E

48.00

stock-summary
Industry P/E

33

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.07

stock-summary
Return on Equity

73.46%

stock-summary
Price to Book

35.14

Revenue and Profits:
Net Sales:
109 Cr
(Quarterly Results - Sep 2025)
Net Profit:
1 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
108.66%
0%
108.66%
6 Months
266.55%
0%
266.55%
1 Year
1024.56%
0%
1024.56%
2 Years
1623.63%
0%
1623.63%
3 Years
2768.89%
0%
2768.89%
4 Years
3087.65%
0%
3087.65%
5 Years
5876.85%
0%
5876.85%

Checkpoint Trend for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Checkpoint Trends Ltd Gains 0.64%: 5 Key Factors Driving the Week’s Momentum

Announcements stock-summary

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

14-Jan-2026 | Source : BSE

Compliance certificate for the quarter ended December 31 2025

Closure of Trading Window

29-Dec-2025 | Source : BSE

Closure of trading window for the financial result for quarter ended December 31 2025

Non-Applicability Of Secretarial Compliance Report For The Year Ended March 31 2025

26-Dec-2025 | Source : BSE

Non-applicability of Secretarial compliance report for the year ended March 31 2025

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
160.84%
EBIT Growth (5y)
23.99%
EBIT to Interest (avg)
0.38
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
7.07
Tax Ratio
24.74%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
10.86%
ROCE (avg)
11.21%
ROE (avg)
17.29%

Valuation key factors

Factor
Value
P/E Ratio
48
Industry P/E
33
Price to Book Value
35.14
EV to EBIT
35.80
EV to EBITDA
35.80
EV to Capital Employed
37.55
EV to Sales
0.57
PEG Ratio
0.06
Dividend Yield
NA
ROCE (Latest)
104.89%
ROE (Latest)
73.46%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 3 FIIs (10.71%)

Promoter with highest holding

None

Highest Public shareholder

Religare Finvest Ltd (5.89%)

Individual Investors Holdings

75.24%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 827.33% vs 4,584.00% in Jun 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 1,366.67% vs 50.00% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "108.59",
          "val2": "11.71",
          "chgp": "827.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.79",
          "val2": "0.09",
          "chgp": "1,888.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "1.32",
          "val2": "0.09",
          "chgp": "1,366.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "1.65%",
          "val2": "0.77%",
          "chgp": "0.88%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 80,106.67% vs -69.39% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 7,150.00% vs -110.00% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "120.31",
          "val2": "0.15",
          "chgp": "80,106.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.89",
          "val2": "-0.01",
          "chgp": "19,000.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "1.41",
          "val2": "-0.02",
          "chgp": "7,150.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "1.57%",
          "val2": "-6.67%",
          "chgp": "8.24%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is -62.12% vs -38.89% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is -115.38% vs 1,200.00% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.25",
          "val2": "0.66",
          "chgp": "-62.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.05",
          "val2": "0.26",
          "chgp": "-119.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.02",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.04",
          "val2": "0.26",
          "chgp": "-115.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-20.00%",
          "val2": "39.39%",
          "chgp": "-59.39%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -55.75% vs -2.59% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 0.00% vs 137.50% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.50",
          "val2": "1.13",
          "chgp": "-55.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.06",
          "val2": "0.03",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.03",
          "val2": "0.03",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "12.00%",
          "val2": "2.65%",
          "chgp": "9.35%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Sep'25 - QoQstock-summary

Sep'25
Jun'25
Change(%)
Net Sales
108.59
11.71
827.33%
Operating Profit (PBDIT) excl Other Income
1.79
0.09
1,888.89%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
1.32
0.09
1,366.67%
Operating Profit Margin (Excl OI)
1.65%
0.77%
0.88%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is 827.33% vs 4,584.00% in Jun 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Sep 2025 is 1,366.67% vs 50.00% in Jun 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
120.31
0.15
80,106.67%
Operating Profit (PBDIT) excl Other Income
1.89
-0.01
19,000.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
1.41
-0.02
7,150.00%
Operating Profit Margin (Excl OI)
1.57%
-6.67%
8.24%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 80,106.67% vs -69.39% in Sep 2024

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is 7,150.00% vs -110.00% in Sep 2024

Nine Monthly Results Snapshot (Standalone) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
0.25
0.66
-62.12%
Operating Profit (PBDIT) excl Other Income
-0.05
0.26
-119.23%
Interest
0.00
0.00
Exceptional Items
0.02
0.00
Standalone Net Profit
-0.04
0.26
-115.38%
Operating Profit Margin (Excl OI)
-20.00%
39.39%
-59.39%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is -62.12% vs -38.89% in Dec 2023

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2024 is -115.38% vs 1,200.00% in Dec 2023

Annual Results Snapshot (Standalone) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
0.50
1.13
-55.75%
Operating Profit (PBDIT) excl Other Income
0.06
0.03
100.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
0.03
0.03
Operating Profit Margin (Excl OI)
12.00%
2.65%
9.35%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is -55.75% vs -2.59% in Mar 2024

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2025 is 0.00% vs 137.50% in Mar 2024

stock-summaryCompany CV
About Checkpoint Trends Ltd stock-summary
stock-summary
Checkpoint Trends Ltd
Micro Cap
Pharmaceuticals & Biotechnology
Checkpoint Trends Limited (Formerly known as Rubra Medicaments Ltd) was established in 1991. The Company name was changed from Rubra Medicaments Limited to Checkpoint Trends Limited in April, 2022. It is presently into the business of trading. The Company possesses great experience in management and providing different kinds of consultancies in India. The main object of the Company is to cater to all categories of clients providing all types of consulting services.
Company Coordinates stock-summary
Company Details
604 6th Floor Meghdoot, Mogul Lines Staff CHSL JVPD Sc Mumbai Maharashtra : 400049
stock-summary
Tel: 91-9167469649
stock-summary
rubraltd@gmail.com
Registrar Details
Bigshare Services Pvt Ltd , G 10 Left Wing Amruta Village , Opp: Yashoda Hospital, Raj Bhavan Road, Somajiguda, Hyderabad